NASDAQ:ORMP

Oramed Pharmaceuticals (ORMP) Stock Forecast, Price & News

$2.57

-0.04 (-1.53%)

(As of 10/2/2023 ET)

Compare

Today's Range: $2.53
▼
$2.60
50-Day Range: $2.51
▼
$3.45
52-Week Range: $1.81
▼
$13.73

Volume: 49,028 shs
Average Volume: 965,942 shs
Market Capitalization: $103.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.00

Oramed Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 639.3% Upside
$19.00 Price Target
Short Interest: Healthy
1.41% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.44
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

769th out of 969 stocks

Pharmaceutical Preparations Industry

371st out of 452 stocks

3.0

Analyst's Opinion

Consensus Rating
Oramed Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.00, Oramed Pharmaceuticals has a forecasted upside of 639.3% from its current price of $2.57.
Amount of Analyst Coverage
Oramed Pharmaceuticals has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.41% of the outstanding shares of Oramed Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Oramed Pharmaceuticals has recently increased by 25.82%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Oramed Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Oramed Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ORMP.

2.5

News and Social Media Coverage

News Sentiment
Oramed Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Oramed Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 10 people have searched for ORMP on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
MarketBeat Follows
93 people have added Oramed Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.00% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 5.82% of the stock of Oramed Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Oramed Pharmaceuticals is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Oramed Pharmaceuticals is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Oramed Pharmaceuticals has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Oramed Pharmaceuticals (NASDAQ:ORMP) Stock

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

ORMP Price History

30 days | 90 days | 365 days | Advanced Chart

ORMP Stock News Headlines

September 21, 2023 | finance.yahoo.com

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

August 2, 2023 | finance.yahoo.com

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

October 2, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

July 25, 2023 | jp.reuters.com

Oramed Pharmaceuticals, Inc.

June 20, 2023 | finance.yahoo.com

Oramed to Present at the 83rd American Diabetes Association Conference

June 17, 2023 | finance.yahoo.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

May 30, 2023 | finance.yahoo.com

ORMP: Advancing Development Efforts in China

May 24, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Hold Rating for Oramed Pharm (ORMP)

October 2, 2023 | Legacy Research (Ad)

Elon Did It Again: This Could be Bigger than Tesla

Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.

May 18, 2023 | msn.com

Canaccord Genuity Maintains Oramed Pharmaceuticals (ORMP) Hold Recommendation

May 18, 2023 | finance.yahoo.com

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

May 16, 2023 | msn.com

Oramed Surges on New Diabetes Treatment

May 15, 2023 | msn.com

Why Oramed Pharmaceuticals Shares Are Trading Higher Today

May 15, 2023 | finance.yahoo.com

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

May 3, 2023 | msn.com

Investing millions, Ben Shapiro joins board of Oramed Pharmaceuticals

May 2, 2023 | marketwatch.com

8-K: ORAMED PHARMACEUTICALS INC.

May 2, 2023 | finance.yahoo.com

Conservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug Company

May 1, 2023 | finance.yahoo.com

Oramed Appoints Ben Shapiro to its Board of Directors

April 5, 2023 | money.usnews.com

Oramed Pharmaceuticals, Inc

March 27, 2023 | finance.yahoo.com

The past year for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable

March 16, 2023 | benzinga.com

Oramed Pharmaceuticals Chief Scientific Officer Sold $200K In Company Stock

March 16, 2023 | benzinga.com

Director of Oramed Pharmaceuticals Makes $141K Buy

March 13, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Hold Rating on Oramed Pharm (ORMP)

February 16, 2023 | finance.yahoo.com

Oramed Pharmaceuticals Inc. (ORMP.TA)

February 9, 2023 | finance.yahoo.com

Oramed Pharmaceuticals Issues Shareholder Update

January 25, 2023 | finance.yahoo.com

ORMP: ORA-D-013-1 Failed To Meet Endpoints; Ending T2D Oral Insulin Efforts

January 12, 2023 | seekingalpha.com

Hot Stocks: CTSH rises on guidance; LOGI slumps; CAT hits 52-week high; ORMP plunges 76%

See More Headlines

Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Company Calendar

Last Earnings: 8/10/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ORMP
CUSIP: N/A
CIK: 1176309
Web: www.oramed.com
Phone: (844) 967-2633
Fax: 972-2566-0004
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $19.00
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +639.3%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,560,000.00
Net Margins: -747.02%
Pretax Margin: -770.00%
Return on Equity: -13.35%
Return on Assets: -12.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 141.49
Quick Ratio: 141.49

Sales & Book Value

Annual Sales: $2.70 million
Price / Sales: 38.34
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.86 per share
Price / Book: 0.67

Miscellaneous

Outstanding Shares: 40,280,000
Free Float: 35,443,000
Market Cap: $103.52 million
Optionable: Optionable
Beta: 1.80

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Nadav Kidron Esq. (Age 49)
Pres, CEO & Exec. Chairman
Comp: $1.11M

Mr. David Silberman CPA (Age 39)
CFO & Treasurer
Comp: $248.04k

Dr. Miriam Kidron Ph.D. (Age 83)
Chief Scientific Officer & Director
Comp: $542.68k

Mr. Joshua Hexter (Age 53)
Chief Operating & Bus. Officer

Mr. Netanel Derovan (Age 47)
Chief Legal Officer & Company Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ORMP Stock - Frequently Asked Questions

Should I buy or sell Oramed Pharmaceuticals stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ORMP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORMP, but not buy additional shares or sell existing shares.
View ORMP analyst ratings or view top-rated stocks.
What is Oramed Pharmaceuticals' stock price forecast for 2023?: 3 Wall Street analysts have issued 12-month price targets for Oramed Pharmaceuticals' shares. Their ORMP share price forecasts range from $3.00 to $35.00. On average, they anticipate the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 639.3% from the stock's current price.
View analysts price targets for ORMP or view top-rated stocks among Wall Street analysts.
How have ORMP shares performed in 2023?: Oramed Pharmaceuticals' stock was trading at $12.03 at the beginning of 2023. Since then, ORMP stock has decreased by 78.6% and is now trading at $2.57.
View the best growth stocks for 2023 here.
Are investors shorting Oramed Pharmaceuticals?: Oramed Pharmaceuticals saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 566,200 shares, an increase of 25.8% from the August 31st total of 450,000 shares. Based on an average daily trading volume, of 203,800 shares, the short-interest ratio is currently 2.8 days.
View Oramed Pharmaceuticals' Short Interest.
When is Oramed Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ORMP earnings forecast.
How were Oramed Pharmaceuticals' earnings last quarter?: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) posted its quarterly earnings data on Thursday, August, 10th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.08. The biotechnology company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.70 million. Oramed Pharmaceuticals had a negative trailing twelve-month return on equity of 13.35% and a negative net margin of 747.02%.

What other stocks do shareholders of Oramed Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).
What is Oramed Pharmaceuticals' stock symbol?: Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."
How do I buy shares of Oramed Pharmaceuticals?: Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Oramed Pharmaceuticals' stock price today?: One share of ORMP stock can currently be purchased for approximately $2.57.
How much money does Oramed Pharmaceuticals make?: Oramed Pharmaceuticals (NASDAQ:ORMP) has a market capitalization of $103.52 million and generates $2.70 million in revenue each year. The biotechnology company earns $-36,560,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.
How can I contact Oramed Pharmaceuticals?: Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The official website for the company is www.oramed.com. The biotechnology company can be reached via phone at (844) 967-2633, via email at ir@oramed.com, or via fax at 972-2566-0004.

This page (NASDAQ:ORMP) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial